Sherene Loi1, Damien Drubay2,3, Sylvia Adams4, Giancarlo Pruneri5, Prudence A Francis1, Magali Lacroix-Triki2, Heikki Joensuu6, Maria Vittoria Dieci7,8, Sunil Badve9, Sandra Demaria10, Robert Gray11, Elisabetta Munzone12, Jerome Lemonnier13, Christos Sotiriou14, Martine J Piccart14, Pirkko-Liisa Kellokumpu-Lehtinen15, Andrea Vingiani16, Kathryn Gray11, Fabrice Andre2,3, Carsten Denkert17, Roberto Salgado1,18, Stefan Michiels2,3. 1. 1 Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia. 2. 2 Gustave Roussy, Université Paris-Saclay, Villejuif, France. 3. 3 Université Paris-Sud, Institut National de la Santé et de la Recherche Médicale, Villejuif, France. 4. 4 New York University School of Medicine, New York, NY. 5. 5 Fondazione Istituto di Ricovero e Cura a Carattere Scientifico-Isituto Nazionale dei Tumori, Universita degli Studi di Milano, Milan, Italy. 6. 7 Helsinki University Central Hospital, Helsinki, Finland. 7. 8 University of Padova, Padova, Italy. 8. 9 Veneto Insitute of Oncology-IOV-IRCCS, Padua, Italy. 9. 10 Indiana University, Indianapolis, IN. 10. 11 Weill-Cornell Medicine, New York, NY. 11. 12 Dana-Farber Cancer Institute, Boston, MA. 12. 13 European institute of Oncology, Milan, Italy. 13. 6 R&D UNICANCER, Paris, France. 14. 14 Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium. 15. 15 Tampere University Hospital, Tampere, Finland. 16. 16 University of Milan, Milan, Italy. 17. 17 Charite Universite Hospital, Berlin, Germany. 18. 18 GZA, Antwerp, Belgium.
Abstract
PURPOSE: The aim of the current study was to conduct a pooled analysis of studies that have investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage triple negative breast cancer (TNBC). METHODS: Participating studies had evaluated the percentage infiltration of stromally located TILs (sTILs) that were quantified in the same manner in patient diagnostic samples of early-stage TNBC treated with anthracycline-based chemotherapy with or without taxanes. Cox proportional hazards regression models stratified by trial were used for invasive disease-free survival (iDFS; primary end point), distant disease-free survival (D-DFS), and overall survival (OS), fitting sTILs as a continuous variable adjusted for clinicopathologic factors. RESULTS: We collected individual data from 2,148 patients from nine studies. Average age was 50 years (range, 22 to 85 years), and 33% of patients were node negative. The average value of sTILs was 23% (standard deviation, 20%), and 77% of patients had 1% or more sTILs. sTILs were significantly lower with older age ( P = .001), larger tumor size ( P = .01), more nodal involvement ( P = .02), and lower histologic grade ( P = .001). A total of 736 iDFS and 548 D-DFS events and 533 deaths were observed. In the multivariable model, sTILs added significant independent prognostic information for all end points (likelihood ratio χ2, 48.9 iDFS; P < .001; χ2, 55.8 D-DFS; P < .001; χ2, 48.5 OS; P < .001). Each 10% increment in sTILs corresponded to an iDFS hazard ratio of 0.87 (95% CI, 0.83 to 0.91) for iDFS, 0.83 (95% CI, 0.79 to 0.88) for D-DFS, and 0.84 (95% CI, 0.79 to 0.89) for OS. In node-negative patients with sTILs ≥ 30%, 3-year iDFS was 92% (95% CI, 89% to 98%), D-DFS was 97% (95% CI, 95% to 99%), and OS was 99% (95% CI, 97% to 100%). CONCLUSION: This pooled data analysis confirms the strong prognostic role of sTILs in early-stage TNBC and excellent survival of patients with high sTILs after adjuvant chemotherapy and supports the integration of sTILs in a clinicopathologic prognostic model for patients with TNBC. This model can be found at www.tilsinbreastcancer.org .
PURPOSE: The aim of the current study was to conduct a pooled analysis of studies that have investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage triple negative breast cancer (TNBC). METHODS: Participating studies had evaluated the percentage infiltration of stromally located TILs (sTILs) that were quantified in the same manner in patient diagnostic samples of early-stage TNBC treated with anthracycline-based chemotherapy with or without taxanes. Cox proportional hazards regression models stratified by trial were used for invasive disease-free survival (iDFS; primary end point), distant disease-free survival (D-DFS), and overall survival (OS), fitting sTILs as a continuous variable adjusted for clinicopathologic factors. RESULTS: We collected individual data from 2,148 patients from nine studies. Average age was 50 years (range, 22 to 85 years), and 33% of patients were node negative. The average value of sTILs was 23% (standard deviation, 20%), and 77% of patients had 1% or more sTILs. sTILs were significantly lower with older age ( P = .001), larger tumor size ( P = .01), more nodal involvement ( P = .02), and lower histologic grade ( P = .001). A total of 736 iDFS and 548 D-DFS events and 533 deaths were observed. In the multivariable model, sTILs added significant independent prognostic information for all end points (likelihood ratio χ2, 48.9 iDFS; P < .001; χ2, 55.8 D-DFS; P < .001; χ2, 48.5 OS; P < .001). Each 10% increment in sTILs corresponded to an iDFS hazard ratio of 0.87 (95% CI, 0.83 to 0.91) for iDFS, 0.83 (95% CI, 0.79 to 0.88) for D-DFS, and 0.84 (95% CI, 0.79 to 0.89) for OS. In node-negative patients with sTILs ≥ 30%, 3-year iDFS was 92% (95% CI, 89% to 98%), D-DFS was 97% (95% CI, 95% to 99%), and OS was 99% (95% CI, 97% to 100%). CONCLUSION: This pooled data analysis confirms the strong prognostic role of sTILs in early-stage TNBC and excellent survival of patients with high sTILs after adjuvant chemotherapy and supports the integration of sTILs in a clinicopathologic prognostic model for patients with TNBC. This model can be found at www.tilsinbreastcancer.org .
Authors: S Gourgou-Bourgade; D Cameron; P Poortmans; B Asselain; D Azria; F Cardoso; R A'Hern; J Bliss; J Bogaerts; H Bonnefoi; E Brain; M J Cardoso; B Chibaudel; R Coleman; T Cufer; L Dal Lago; F Dalenc; E De Azambuja; M Debled; S Delaloge; T Filleron; J Gligorov; M Gutowski; W Jacot; C Kirkove; G MacGrogan; S Michiels; I Negreiros; B V Offersen; F Penault Llorca; G Pruneri; H Roche; N S Russell; F Schmitt; V Servent; B Thürlimann; M Untch; J A van der Hage; G van Tienhoven; H Wildiers; J Yarnold; F Bonnetain; S Mathoulin-Pélissier; C Bellera; T S Dabakuyo-Yonli Journal: Ann Oncol Date: 2015-02-27 Impact factor: 32.976
Authors: R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi Journal: Ann Oncol Date: 2014-09-11 Impact factor: 32.976
Authors: Carsten Denkert; Stephan Wienert; Audrey Poterie; Sibylle Loibl; Jan Budczies; Sunil Badve; Zsuzsanna Bago-Horvath; Anita Bane; Shahinaz Bedri; Jane Brock; Ewa Chmielik; Matthias Christgen; Cecile Colpaert; Sandra Demaria; Gert Van den Eynden; Giuseppe Floris; Stephen B Fox; Dongxia Gao; Barbara Ingold Heppner; S Rim Kim; Zuzana Kos; Hans H Kreipe; Sunil R Lakhani; Frederique Penault-Llorca; Giancarlo Pruneri; Nina Radosevic-Robin; David L Rimm; Stuart J Schnitt; Bruno V Sinn; Peter Sinn; Nicolas Sirtaine; Sandra A O'Toole; Giuseppe Viale; Koen Van de Vijver; Roland de Wind; Gunter von Minckwitz; Frederick Klauschen; Michael Untch; Peter A Fasching; Toralf Reimer; Karen Willard-Gallo; Stefan Michiels; Sherene Loi; Roberto Salgado Journal: Mod Pathol Date: 2016-07-01 Impact factor: 7.842
Authors: Emma Nolan; Peter Savas; Antonia N Policheni; Phillip K Darcy; François Vaillant; Christopher P Mintoff; Sathana Dushyanthen; Mariam Mansour; Jia-Min B Pang; Stephen B Fox; Charles M Perou; Jane E Visvader; Daniel H D Gray; Sherene Loi; Geoffrey J Lindeman Journal: Sci Transl Med Date: 2017-06-07 Impact factor: 17.956
Authors: Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Edith A Perez; John A Olson; JoAnne Zujewski; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; James N Atkins; Jeffrey L Berenberg; George W Sledge Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: Sylvia Adams; Robert J Gray; Sandra Demaria; Lori Goldstein; Edith A Perez; Lawrence N Shulman; Silvana Martino; Molin Wang; Vicky E Jones; Thomas J Saphner; Antonio C Wolff; William C Wood; Nancy E Davidson; George W Sledge; Joseph A Sparano; Sunil S Badve Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: H R Ali; E Provenzano; S-J Dawson; F M Blows; B Liu; M Shah; H M Earl; C J Poole; L Hiller; J A Dunn; S J Bowden; C Twelves; J M S Bartlett; S M A Mahmoud; E Rakha; I O Ellis; S Liu; D Gao; T O Nielsen; P D P Pharoah; C Caldas Journal: Ann Oncol Date: 2014-06-09 Impact factor: 32.976
Authors: Zuzana Kos; Elvire Roblin; Rim S Kim; Stefan Michiels; Brandon D Gallas; Weijie Chen; Koen K van de Vijver; Shom Goel; Sylvia Adams; Sandra Demaria; Giuseppe Viale; Torsten O Nielsen; Sunil S Badve; W Fraser Symmans; Christos Sotiriou; David L Rimm; Stephen Hewitt; Carsten Denkert; Sibylle Loibl; Stephen J Luen; John M S Bartlett; Peter Savas; Giancarlo Pruneri; Deborah A Dillon; Maggie Chon U Cheang; Andrew Tutt; Jacqueline A Hall; Marleen Kok; Hugo M Horlings; Anant Madabhushi; Jeroen van der Laak; Francesco Ciompi; Anne-Vibeke Laenkholm; Enrique Bellolio; Tina Gruosso; Stephen B Fox; Juan Carlos Araya; Giuseppe Floris; Jan Hudeček; Leonie Voorwerk; Andrew H Beck; Jen Kerner; Denis Larsimont; Sabine Declercq; Gert Van den Eynden; Lajos Pusztai; Anna Ehinger; Wentao Yang; Khalid AbdulJabbar; Yinyin Yuan; Rajendra Singh; Crispin Hiley; Maise Al Bakir; Alexander J Lazar; Stephen Naber; Stephan Wienert; Miluska Castillo; Giuseppe Curigliano; Maria-Vittoria Dieci; Fabrice André; Charles Swanton; Jorge Reis-Filho; Joseph Sparano; Eva Balslev; I-Chun Chen; Elisabeth Ida Specht Stovgaard; Katherine Pogue-Geile; Kim R M Blenman; Frédérique Penault-Llorca; Stuart Schnitt; Sunil R Lakhani; Anne Vincent-Salomon; Federico Rojo; Jeremy P Braybrooke; Matthew G Hanna; M Teresa Soler-Monsó; Daniel Bethmann; Carlos A Castaneda; Karen Willard-Gallo; Ashish Sharma; Huang-Chun Lien; Susan Fineberg; Jeppe Thagaard; Laura Comerma; Paula Gonzalez-Ericsson; Edi Brogi; Sherene Loi; Joel Saltz; Frederick Klaushen; Lee Cooper; Mohamed Amgad; David A Moore; Roberto Salgado Journal: NPJ Breast Cancer Date: 2020-05-12
Authors: Mohamed Amgad; Elisabeth Specht Stovgaard; Eva Balslev; Jeppe Thagaard; Weijie Chen; Sarah Dudgeon; Ashish Sharma; Jennifer K Kerner; Carsten Denkert; Yinyin Yuan; Khalid AbdulJabbar; Stephan Wienert; Peter Savas; Leonie Voorwerk; Andrew H Beck; Anant Madabhushi; Johan Hartman; Manu M Sebastian; Hugo M Horlings; Jan Hudeček; Francesco Ciompi; David A Moore; Rajendra Singh; Elvire Roblin; Marcelo Luiz Balancin; Marie-Christine Mathieu; Jochen K Lennerz; Pawan Kirtani; I-Chun Chen; Jeremy P Braybrooke; Giancarlo Pruneri; Sandra Demaria; Sylvia Adams; Stuart J Schnitt; Sunil R Lakhani; Federico Rojo; Laura Comerma; Sunil S Badve; Mehrnoush Khojasteh; W Fraser Symmans; Christos Sotiriou; Paula Gonzalez-Ericsson; Katherine L Pogue-Geile; Rim S Kim; David L Rimm; Giuseppe Viale; Stephen M Hewitt; John M S Bartlett; Frédérique Penault-Llorca; Shom Goel; Huang-Chun Lien; Sibylle Loibl; Zuzana Kos; Sherene Loi; Matthew G Hanna; Stefan Michiels; Marleen Kok; Torsten O Nielsen; Alexander J Lazar; Zsuzsanna Bago-Horvath; Loes F S Kooreman; Jeroen A W M van der Laak; Joel Saltz; Brandon D Gallas; Uday Kurkure; Michael Barnes; Roberto Salgado; Lee A D Cooper Journal: NPJ Breast Cancer Date: 2020-05-12
Authors: Luke J Nelson; Heather J Wright; Nguyen B Dinh; Kevin D Nguyen; Olga V Razorenova; F Scott Heinemann Journal: Am J Pathol Date: 2019-12-13 Impact factor: 4.307
Authors: Mei-Yin C Polley; Roberto A Leon-Ferre; Samuel Leung; Angela Cheng; Dongxia Gao; Jason Sinnwell; Heshan Liu; David W Hillman; Abraham Eyman-Casey; Judith A Gilbert; Vivian Negron; Judy C Boughey; Minetta C Liu; James N Ingle; Krishna Kalari; Fergus Couch; Jodi M Carter; Daniel W Visscher; Torsten O Nielsen; Matthew P Goetz Journal: Breast Cancer Res Treat Date: 2021-01-03 Impact factor: 4.872
Authors: Rachel L Stewart; Katherine L Updike; Rachel E Factor; N Lynn Henry; Kenneth M Boucher; Philip S Bernard; Katherine E Varley Journal: Cancer Res Date: 2019-05-02 Impact factor: 12.701
Authors: Yuan Yuan; Jin Sun Lee; Susan E Yost; Sierra Min Li; Paul H Frankel; Christopher Ruel; Daniel Schmolze; Kim Robinson; Aileen Tang; Norma Martinez; Daphne Stewart; James Waisman; Laura Kruper; Veronica Jones; Andrea Menicucci; Sahra Uygun; Erin Yoder; Bastiaan van der Baan; John H Yim; Christina Yeon; George Somlo; Joanne Mortimer Journal: Oncologist Date: 2020-11-08